© 2002 by Oxford University Press and the Maryland Psychiatric Research Center (MPRC)
The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia
VA Desert Pacific Mental Illness Research Education and Clinical Center (MIRECC); Department Chair of Psychiatry, VA Greater Los Angeles Health Care System; and Professor and Vice Chair, Department of Psychiatry, University of California Los Angeles, CA
Professor and Director of the Division of Health Services Research, Department of Psychiatry, Mount Sinai School of Medicine of New York University New York, NY; and Evaluation Director, Veterans Affairs New York Healthcare System, Mental Illness Research, Education, and Clinical Center New York, NY
Schizophrenia Module, Texas Medication Algorithm Project, and Professor of Psychiatry, University of Texas Health Science Center San Antonio, TX
Maryland Psychiatric Research Center Baltimore, MD
University of Illinois Chicago, IL
Behavioral Health Services for the North Shore Long Island Jewish Health System and the Doctor Richard Feinberg Professor in Schizophrenia Research, Albert Einstein College of Medicine New York, NY
Department of Psychiatry, University of North Carolina at Chapel Hill Chapel Hill, NC
Hillside Hospital Glen Oaks, NY
Send reprint requests to Dr. S. Marder, MIRECC/210A, West Los Angeles VA Health Care Center, 11301 Wilshire Boulevard, Los Angeles, CA 90073; e-mail: marder{at}ucla.edu
This report summarizes the recommendations from a consensus meeting that focused on specific questions regarding the pharmacotherapy of schizophrenia. The issues were selected because there was evidence that experts had recently disagreed about the evidence supporting a particular practice or when there were substantial variations in a clinical practice indicating that there was disagreement among clinicians. The group of experts was able to reach a consensus regarding the evidence base pertaining to the following issues: First generation (FGAs) and second generation (SGAs) antipsychotics as first line agents; the duration of antipsychotic trials; the effectiveness of clozapine and other agents for treatment refractory schizophrenia; risk of tardive dyskinesia on FGAs and SGAs; differences among antipsychotics for different dimensions of psychopathology; and side effect monitoring for various antipsychotics.
Keywords: Schizophrenia / antipsychotics / tardive dyskinesia / evidence-based practice / clozapine
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. S. Young, N. Niv, A. N. Cohen, C. Kessler, and K. McNagny The Appropriateness of Routine Medication Treatment for Schizophrenia Schizophr Bull, November 7, 2008; (2008) sbn138v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Bratti, J. M. Kane, and S. R. Marder Chronic Restlessness With Antipsychotics Am J Psychiatry, November 1, 2007; 164(11): 1648 - 1654. [Full Text] [PDF]
|
|
|
|
 |
|
 R. L Dufresne Weighing In: Emergent Diabetes Mellitus and Second-Generation Antipsychotics Ann. Pharmacother., October 1, 2007; 41(10): 1725 - 1727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 References PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2. [Full Text]
|
|
|
|
 |
|
 A. M. Mortimer and A. O. Ahmed Al-Agib Quality Of Life In Schizophrenia On Conventional Versus Atypical Antipsychotic Medication: A Comparative Cross-Sectional Study International Journal of Social Psychiatry, March 1, 2007; 53(2): 99 - 107. [Abstract] [PDF]
|
|
|
|
 |
|
 O. Runcie, M. Boilson, and R. Hamilton Monitoring weight and blood glucose in in-patients: how helpful is a protocol? Psychiatr. Bull., March 1, 2007; 31(3): 88 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L Bettinger, G. Shuler, D. R Jones, and J. P Wilson Schizophrenia: Multi-Attribute Utility Theory Approach to Selection of Atypical Antipsychotics Ann. Pharmacother., February 1, 2007; 41(2): 201 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Young, D. C. Mohr, M. Meterko, M. N. Seibert, and G. McGlynn Psychiatrists' Self-Reported Adherence to Evidence-Based Prescribing Practices in the Treatment of Schizophrenia Psychiatr Serv, January 1, 2006; 57(1): 130 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Citrome Metabolic Syndrome and Cardiovascular Disease J Psychopharmacol, November 1, 2005; 19(6_suppl): 84 - 93. [Abstract] [PDF]
|
|
|
|
|
|
L. Citrome and D. Yeomans Do guidelines for severe mental illness promote physical health and well-being? J Psychopharmacol, November 1, 2005; 19(6_suppl): 102 - 109. [Abstract] [PDF]
|
|
|
|
|
|
H. Ascher-Svanum, M. D. Stensland, B. J. Kinon, and G. D. Tollefson Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic J Psychopharmacol, November 1, 2005; 19(6_suppl): 110 - 117. [Abstract] [PDF]
|
|
|
|
 |
|
 W. Gaebel, S. Weinmann, N. Sartorius, W. Rutz, and J. S. McIntyre Schizophrenia practice guidelines: international survey and comparison The British Journal of Psychiatry, September 1, 2005; 187(3): 248 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Simon, C. Lauber, K. Ludewig, H. Braun-Scharm, D. S. Umbricht, and for the Swiss Early Psychosis Project General practitioners and schizophrenia: results from a Swiss survey The British Journal of Psychiatry, September 1, 2005; 187(3): 274 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Akhtar, C. Kelly, A. Gallagher, and J. R Petrie Review: Newer antipsychotic agents, carbohydrate metabolism and cardiovascular risk The British Journal of Diabetes & Vascular Disease, September 1, 2004; 4(5): 303 - 309. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Freedman Schizophrenia N. Engl. J. Med., October 30, 2003; 349(18): 1738 - 1749. [Full Text] [PDF]
|
|